Friday, 27 November 2020

FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma



source https://www.pharmatutor.org/pharma-news/2020/fda-approves-y-mabs-danyelza-naxitamab-gqgk-for-the-treatment-of-neuroblastoma

No comments:

Post a Comment

Pharmaceutical Industry and pharma / Life Sciences institute openings 2025

  Intas Pharma Walk in Drive for M.Pharm, B.Pharm | Multiple Posts M.Pharma / B.Pharma. Injectable/Parenteral/Sterile - Aseptic, Manufacturi...